Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Garivulimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Grisnilimab, an antibody targeting CD7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Letaplimab, an antibody targeting IAP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rimteravimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tecaginlimab, an antibody targeting CD40 × 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pivekimab, an antibody targeting IL3RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lepunafusp, an antibody targeting TfR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ivicentamab, an antibody targeting CD37.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ginisortamab, an antibody targeting GREM1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bafisontamab, an antibody targeting EGFR × MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dresbuxelimab, an antibody targeting CD73.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Betifisolimab, an antibody targeting PD-L1.